Observational studyCells2022

Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.

Marina Boziki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.